ENDPOINTS

#ASCO25: Roche confirms OS benefit for PI3K inhibitor Itovebi in breast cancer

The final overall survival results are in for Roche’s PI3K inhibitor, known as Itovebi, in certain forms of breast cancer. And they bode well for the company and patients. After a median 34.2 months of ...

May 22, 2025 - 22:04
 0
#ASCO25: Roche confirms OS benefit for PI3K inhibitor Itovebi in breast cancer
The final overall survival results are in for Roche’s PI3K inhibitor, known as Itovebi, in certain forms of breast cancer. And they bode well for the company and patients. After a median 34.2 months of ...
Read More

Tags:

Previous Article

Is the world ready for a catastrophic solar storm?

Next Article

#ASCO25: Jazz outlines full survival data for lung cancer drug Zepzelca

Related Posts

Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent

Endpoints 100 biotech survey: Welcome to the summer of ...

May 20, 2025  0

David Liu, Sam Sternberg unveil new way to insert big genes in human cells

David Liu, Sam Sternberg unveil new way to insert big g...

May 19, 2025  0

Ex-FDA chief Robert Califf thinks RFK Jr.'s vaccine opinions are relevant

Ex-FDA chief Robert Califf thinks RFK Jr.'s vaccine opi...

May 14, 2025  0